SCHEMBL1776385

SCHEMBL1776385

Cc1cc(N)c2cnn(-c3cccc(C(=O)O)c3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 2/20 0.46
KDM4E B2RXH2 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
USP2 O75604 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MYC P01106 1/20 0.46
POLB P06746 1/20 0.46
HSPA1A P0DMV8 1/20 0.46
ALOX15 P16050 1/20 0.46
NR4A1 P22736 1/20 0.46
PTPN7 P35236 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NR3C1 P04150 9/20 0.46
NPC1 O15118 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3972212 0.87 XDH (0.51) MAPTMEN1KMT2AGAAKDM4E
SCHEMBL9609077 0.87 NR3C1 (0.46) MEN1KMT2AGAAKDM4EBLM
SCHEMBL1775488 0.87 NR3C1 (0.48) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL1773970 0.86 NR3C1 (0.45) MAPTL3MBTL1MEN1KMT2AGAA
SCHEMBL4401018 0.84 NPC1 (0.56) MAPTKMT2AKDM4EBLMHSD17B10
SCHEMBL13884763 0.84 NR3C1 (0.44) MEN1KMT2AKDM4EBLMHSD17B10
SCHEMBL304081 0.84 RAB9A (0.47) MAPTMEN1KMT2AKDM4EBLM
SCHEMBL303719 0.83 TDP1 (0.45) MAPTL3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL9609078 0.78 NR3C1 (0.40) MAPTL3MBTL1MEN1KMT2AGAA
SCHEMBL9609001 0.75 NR3C1 (0.44) MEN1KMT2ANR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013185-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-05-30 EP disclosed
EP-2013185-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-05-30 EP disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-20100016331-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-01-21 US disclosed
WO-2009074590-A1 N- (2 { [1-PHENYL-1H-INDAZ0L-4-YL] AMINO} PROPYL) -SULFONAMIDE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS GLAXO GROUP LIMITED (GB) 2009-06-18 WO disclosed
WO-2009050244-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050243-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 WO disclosed
WO-2009050221-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 WO disclosed
EP-2013185-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2009-01-14 EP disclosed
WO-2008043788-A2 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-17 WO disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
WO-2007122165-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-01 WO disclosed
WO-2007122165-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265326-A1 NOVEL COMPOUNDS CCL11, MRGPRX2, LTB4R2 MAPT 1836/4885L3MBTL1 4840/4885MEN1 4193/4885
US-20100016331-A1 NOVEL COMPOUNDS TSLP, LTB4R2, LTB4R MAPT 2087/4885L3MBTL1 4864/4885MEN1 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.